leisure time -WSS

leisure time

author：focus 2025-09-03 09:21:53 - browse：67224

The Dr. Gary B. and Pamela S. Williams Tower in Summa Health System's Akron Campus — Summa Health

General Catalysts’s grand vision for a venture capital-owned hospital system seamlessly blending AI and tech into everyday appointments and rewarding staff for keeping patients healthy might sound alluring. But the firm’s bold experiment is facing hurdles even before it has started as the community served by the health system it hopes to buy is pushing back.

The Health Assurance Transformation Corp., a General Catalyst entity known as HATCo, unveiled plans last month to acquire Akron safety net provider Summa Health. But since the announcement, residents and local officials have raised questions about who the deal benefits, and who gets left behind.

On Thursday, the Mayor of Akron plans to press HATCo’s chief executive, Marc Harrison, who previously led Intermountain Health, on whether his plan is a profit play or a longer-term investment in the community. At the forefront are citizens’ concerns that the deal will drive up costs, eliminate jobs, reduce the quality of care or even shutter one of just two major hospital systems in the area, about a fifth of whose patients are on Medicaid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What Kate Middleton's cancer revelation might teach the world

focus

WSS

'Patient friction coefficient' can gauge a clinical trial's patient burden

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Erich Jarvis studies song birds to learn about human stuttering

Testing GLP

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

leisure time

leisure time

Wikipedia

Affirmative action in medical school literally saved lives

Medicare Advantage insurers pressure Biden for bigger payments

How to save PrEP access — and even expand it

Asbestos ban is immediate, but health effects will linger for decades

Bright Health sells Medicare Advantage business to Molina

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The FDA must approve intranasal treatments for anaphylaxis

Bright Health sells Medicare Advantage business to Molina

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Wikipedia

A single drug, study failures leave Anavex with nothing but cash

Ahead of JPM, here's who's profiting most in health care

Goldman Sachs launches $650M fund for life science investments

This gene therapy has record $4.25 million price. It's saved children.

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Why psychiatrists like me stop taking insurance

focus

focus

knowledge

entertainment